<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03015311</url>
  </required_header>
  <id_info>
    <org_study_id>2016CXGC07</org_study_id>
    <secondary_id>2016-I2M-1-006</secondary_id>
    <nct_id>NCT03015311</nct_id>
  </id_info>
  <brief_title>Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients</brief_title>
  <acronym>STEP</acronym>
  <official_title>Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) is a
      2-arm, multi-center, prospective, randomized, open-labeled, blinded-endpoint trial. The
      purpose of this trial is to test whether a treatment program aimed at reducing systolic blood
      pressure (SBP) to a lower goal (&lt;130 mmHg, intensive treatment) than currently recommended
      (&lt;150 mmHg, standard treatment) will reduce CVD risk among persons between 60-80 years of
      old. Furthermore, this trial will also examine the effect of blood pressure APP management
      strategy via WeChat network on medication compliance, blood pressure control and CVD
      benefits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension is highly prevalent in the adult population in China, and its burden is rapidly
      increasing among persons older than 60 years of age. Elevated blood pressure (BP) is an
      important public health concern which contributes to several adverse health outcomes,
      especially coronary heart disease, stroke, heart failure, chronic kidney disease, and decline
      in cognitive function. Clinical trials have shown that a lower systolic blood pressure goal
      will lead to greater reduction in cardiovascular disease (CVD) incidence, but the effect of
      intensive treatment of systolic blood pressure below 120 mm Hg in reducing of CVD risk has
      long been debated. In particularly, among the elderly hypertensive patients aged 60 years or
      older, the most appropriate targets for blood pressure lowering to reduce cardiovascular
      events still remain uncertain.

      The STEP trial will randomize about 8000 participants aged between 60 and 80 years with
      SBP≥140 mm Hg and &lt;190 mm Hg, and without a history of atherothrombotic or hemorrhagic
      stroke. Target SBP goals are 110-130 vs 130-150 mm Hg, respectively. The purpose of the STEP
      trial is to test whether a treatment program aimed at reducing systolic blood pressure (SBP)
      to a lower goal (&lt;130 mmHg, intensive treatment) than currently recommended (&lt;150 mmHg,
      standard treatment) will reduce CVD risk among hypertensive patients between 60-80 years.
      Participants will be recruited at approximately 40 clinic centers in China within
      approximately a 1-year period, and will be followed for 4 years. Furthermore, this trial will
      also examine the effect of blood pressure APP management strategy via WeChat network on
      medication compliance, blood pressure control and CVD benefits.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of major CVD events</measure>
    <time_frame>4 years</time_frame>
    <description>A composite end-point comprised of myocardial infarction (MI), first occurrence of symptomatic stroke ( ischemic or hemorrhagic, fatal or nonfatal), hospitalization for unstable angina or acute decompensated heart failure, coronary revascularization (percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG]), and death from cardiovascular causes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major coronary events</measure>
    <time_frame>4 years</time_frame>
    <description>Major coronary events comprised of myocardial infarction (MI), hospitalization for unstable angina or acute decompensated heart failure, coronary revascularization (percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG]), and death from cardiovascular causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First occurrence of symptomatic stroke ( ischemic or hemorrhagic, fatal or nonfatal)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for unstable angina</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for acute decompensated heart failure</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coronary revascularization (percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG])</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First occurrence of diabetes mellitus</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in cognitive function</measure>
    <time_frame>4 years</time_frame>
    <description>Decline in cognitive function includes sensory disturbance, memory disorders and thinking disorders, which is assessed by mini-mental state examination (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in renal function or development of end stage renal disease (ESRD)</measure>
    <time_frame>4 years</time_frame>
    <description>Decline in renal function is assessed by any of the following: (1) For patients with chronic kidney disease (eGFR &lt;60 ml per minute per 1.73 m2) at baseline, the renal outcome was a composite of a decrease in the eGFR of 50% or more (confirmed by a subsequent laboratory test) or the development of ESRD requiring long-term dialysis or kidney transplantation; or (2) For participants without chronic kidney disease at baseline, the renal outcome was defined by a decrease in the eGFR of 30% or more to a value of less than 60 ml per minute per 1.73 m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major artery function changes</measure>
    <time_frame>4 years</time_frame>
    <description>Major artery function changes are assessed by a composite of decrease in the ankle brachial index [ABI], brachial-ankle pulse wave velocity(baPWV), or brachial artery flow-mediated dilation [FMD].
ABI and baPWV,well-established non-invasive techniques for evaluating obstruction and stiffness of peripheral artery respectively, are considered for the purposes of cardiovascular risk assessment. ABI is the ratio of the average systolic blood pressure measured in brachial/ankle, and an ABI between and including 0.9 and 1.2 is considered normal, while a lesser than 0.9 indicates arterial disease. The unit measure of baPWV value is cm per second.
FMD serves as an index of nitric oxide (NO)-mediated endothelium-dependent vasodilator function in humans and is regarded as a surrogate marker of cardiovascular disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Primary Hypertension</condition>
  <arm_group>
    <arm_group_label>Intensive BP control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBP within 110 - &lt;130 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 110 - &lt;130 mm Hg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard BP control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SBP within 130 - &lt;150 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 130 - &lt;150 mm Hg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive BP control</intervention_name>
    <description>For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.</description>
    <arm_group_label>Intensive BP control</arm_group_label>
    <other_name>Lower target for reducing SBP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard BP control</intervention_name>
    <description>For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.</description>
    <arm_group_label>Standard BP control</arm_group_label>
    <other_name>Standard target for reducing SBP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Systolic BP between 140-190 mm Hg in the three screening visits or currently under
             anti-hypertension treatment；

          2. An age of 60 - 80 years old；

          3. Signed the written informed consent.

        Exclusion Criteria:

          1. Systolic BP≥190 mm Hg, or diastolic BP &lt;60 mm Hg;

          2. Known secondary cause of hypertension;

          3. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not
             lacunar infarction and transient ischemic attack [TIA]);

          4. Hospitalization for myocardial infarction or unstable angina within the previous 6
             months;

          5. Coronary revascularization (PCI or CABG) within the previous 12 months;

          6. Planned to perform coronary revascularization (PCI or CABG) in the future 12 months;

          7. History of sustained atrial fibrillation or Ventricular arrhythmias at entry
             influencing the measurement of electronic blood pressure；

          8. NYHA class III-IV heart failure at entry or hospitalization for exacerbation of
             chronic heart failure within the previous 6 months;

          9. Severe valvular disease or valvular disease likely to require surgery or percutaneous
             valve replacement during the trial;

         10. Dilated or hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart
             disease;

         11. Uncontrolled diabetes (serum fasting glucose ≥200 mg/dl [11.1 mmol/L], HbA1&gt;8%);

         12. Lab tests indicating abnormal liver or kidney function (ALT more than 3 times the
             upper limit of normal value, or end stage renal disease (ESRD) on dialysis, or
             estimated glomerular filtration rate (eGFR) &lt;30 mL/min, or serum creatine &gt;2.5 mg/dl
             [&gt;221 umol/L];

         13. Severe somatic disease such as cancer;

         14. Severe cognitive impairment or mental disorders;

         15. Participating in other clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Cai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital affiliated to Capical Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bei Jing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences, FuWai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuanwu hospital of capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Pinggu Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Cardiovascular Institute</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huizhou Municipal Central Hospital</name>
      <address>
        <city>Huizhou</city>
        <state>Guangdong</state>
        <zip>516001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital to Medical College Shantou University Guangdong</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen Sun Yat-sen Cardiovascular Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi University of Chinese Medicine</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kailua General Hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Hebei North University</name>
      <address>
        <city>Zhangjiakou</city>
        <state>Hebei</state>
        <zip>075000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hong xinglong center hospital</name>
      <address>
        <city>Shuangyashan</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospitalof Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhoukou City Central Hospital</name>
      <address>
        <city>Zhoukou</city>
        <state>Henan</state>
        <zip>466000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kang Ya Hospita</name>
      <address>
        <city>Yiyang</city>
        <state>Hunan</state>
        <zip>413000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Baotou Medical College</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhenjiang First People's Hospital</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the Second Affiliated Hospitalof NanChang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benxi Railway Hospital</name>
      <address>
        <city>Benxi</city>
        <state>Liaoning</state>
        <zip>117000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Yinchuan</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jining First People's Hospital</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>272011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai general hospital, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi caidiovascular hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030024</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Academy of Medical Sciences, Shanxi Dayi Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, Xian Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Medicine , National Taiwan University</name>
      <address>
        <city>Taibei</city>
        <state>Taiwan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pingjin Hospital, Logistics University of PAPF</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300162</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the People's Hospital of Ji Xian Distric</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yan'an Hospital affiliated to kunming medical university, Yunnan Cardiovascular Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650101</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Kunming</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang Y, Peng X, Nie X, Chen L, Weldon R, Zhang W, Xiao D, Cai J. Burden of hypertension in China over the past decades: Systematic analysis of prevalence, treatment and control of hypertension. Eur J Prev Cardiol. 2016 May;23(8):792-800. doi: 10.1177/2047487315617105. Epub 2015 Nov 24. Review.</citation>
    <PMID>26603746</PMID>
  </reference>
  <reference>
    <citation>SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. Erratum in: N Engl J Med. 2017 Dec 21;377(25):2506.</citation>
    <PMID>26551272</PMID>
  </reference>
  <reference>
    <citation>ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14.</citation>
    <PMID>20228401</PMID>
  </reference>
  <reference>
    <citation>Probstfield JL, Applegate WB, Borhani NO, Curb JD, Cutler JA, Davis BR, Furberg CD, Hawkins CM, Lakatos E, Page LB, et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clin Exp Hypertens A. 1989;11(5-6):973-89.</citation>
    <PMID>2676266</PMID>
  </reference>
  <reference>
    <citation>JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008 Dec;31(12):2115-27. doi: 10.1291/hypres.31.2115.</citation>
    <PMID>19139601</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2017</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Jun Cai</investigator_full_name>
    <investigator_title>Director, Hypertension Center</investigator_title>
  </responsible_party>
  <keyword>Blood pressure control</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

